Identifying and Caring for Individuals With Inherited Cancer Syndrome

Description

This trial examines approaches to identify and care for individuals with inherited cancer syndrome. The purpose of this study is to offer no cost genetic testing to the general public. Researchers hope to learn the value of providing broad, public-wide testing for high risk cancer types (like hereditary breast and ovarian cancer or Lynch syndromes) instead of only testing people whose families are known to be high risk.

Conditions

BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome, Breast Ductal Carcinoma In Situ, Hematopoietic and Lymphoid System Neoplasm, Hereditary Neoplastic Syndrome, Lynch Syndrome, Malignant Solid Neoplasm

Talk to us

Study Overview

On this page

Study Details

Study overview

This trial examines approaches to identify and care for individuals with inherited cancer syndrome. The purpose of this study is to offer no cost genetic testing to the general public. Researchers hope to learn the value of providing broad, public-wide testing for high risk cancer types (like hereditary breast and ovarian cancer or Lynch syndromes) instead of only testing people whose families are known to be high risk.

Approaches to Identify and Care for Individuals With Inherited Cancer Syndromes

Identifying and Caring for Individuals With Inherited Cancer Syndrome

Condition
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome
Intervention / Treatment

-

Contacts and Locations

Portland

Providence Portland Medical Center, Portland, Oregon, United States, 97213

Portland

OHSU Knight Cancer Institute, Portland, Oregon, United States, 97239

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ALL COHORTS: 18 years of age or older
  • * Retrospective COHORT A: Per HIPAA waiver, Retrospective Cohort A will not actively consent
  • * Retrospective COHORT A: Patients may or may not be diagnosed with cancer
  • * Retrospective COHORT A: Patients have received genetic counseling in the past 5 years
  • * Retrospective COHORT A: Patients have genetic variants that include BRCA1, BRCA2 and/or Lynch syndrome
  • * COHORT A: Per Health Insurance Portability and Accountability Act (HIPAA) waiver, Cohort A returns survey as consent
  • * COHORT A: Patients may or may not be diagnosed with cancer
  • * COHORT A: Patients have received genetic counseling in the past 1 - 2 years
  • * COHORT A: Patients have genetic variants that include BRCA1, BRCA2 and/or Lynch syndrome
  • * COHORT A: INCLUSIVE of no contact list to exclude from Cohort B
  • * COHORT B: Creation of secure Medable account
  • * COHORT B: Consent to this project, either hard or electronic signature
  • * COHORT B: Consent to the Healthy Oregon Project (HOP) repository, either hard or electronic signature
  • * COHORT B: Choosing to submit a deoxyribonucleic acid (DNA) sample
  • * COHORT B: Patients diagnosed with any National Cancer Institute (NCI)-reportable cancers, including ductal carcinoma in situ (DCIS) and/or in situ breast cancer
  • * COHORT B: Must have had an encounter within past twelve months
  • * COHORT B: Exclude Cohort A
  • * COHORT C: Creation of secure Medable account
  • * COHORT C: Consent to this project, either hard or electronic signature
  • * COHORT C: Consent to the HOP repository, either hard or electronic signature
  • * COHORT C: Choosing to submit a DNA sample

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

OHSU Knight Cancer Institute,

Jackilen Shannon, Ph.D., PRINCIPAL_INVESTIGATOR, OHSU Knight Cancer Institute

Study Record Dates

2030-06-10